Home > Cannabis Research > Cannabis Use Disorder Treatment

Cannabis Use Disorder Treatment

Name: Cannabis Use Disorder Treatment: Evidence-Based Options
Creator: Ryan S. Sultan, MD
Published: 2026-03-28

Evidence-Based Options for Recovery

From behavioral therapies to digital therapeutics: what works for cannabis use disorder, what does not, and what is on the horizon

Evidence-Based Psychotherapies

CBT, MET, CM

FDA-Approved Medications

A critical treatment gap

36.8%

Adolescent Completion Rate

TEDS 2018-2021

PAWS

AI Digital Therapeutic

Sultan Lab, Columbia

Cannabis use disorder is a treatable condition. While it lacks the pharmacological armamentarium available for alcohol or opioid use disorders, behavioral therapies for CUD have a strong evidence base, and new approaches -- including AI-powered digital therapeutics -- are expanding the treatment landscape. Understanding your options is the first step toward recovery.

Schedule Treatment Consultation

Quick Answer:

The most effective treatment for cannabis use disorder combines behavioral therapies: Cognitive Behavioral Therapy (CBT) to identify triggers and build coping skills, Motivational Enhancement Therapy (MET) to build internal motivation, and Contingency Management (CM) to reinforce abstinence. There are no FDA-approved medications for CUD yet, but several are under investigation. Treating co-occurring conditions (ADHD, depression, anxiety) is essential -- untreated comorbidities are the most common driver of relapse. Dr. Sultan's PAWS project at Columbia is developing an AI-powered digital therapeutic to provide personalized, real-time support between clinical sessions. Recovery is achievable, and early intervention produces better outcomes.

-- Ryan S. Sultan, MD, Assistant Professor of Clinical Psychiatry, Columbia University

Recognizing Cannabis Use Disorder

Before treatment can begin, the condition must be recognized. Cannabis use disorder (CUD) is diagnosed using the DSM-5 criteria, which specify 11 symptoms. Meeting 2 or more criteria within a 12-month period qualifies for a diagnosis, with severity classified as mild (2-3 criteria), moderate (4-5), or severe (6+). For the complete diagnostic criteria, see Cannabis Use Disorder: Signs, Symptoms & Treatment.

The core features of CUD include: using more cannabis than intended, unsuccessful attempts to cut down or quit, spending excessive time obtaining or using cannabis, craving, failure to meet obligations at work, school, or home, continued use despite social or interpersonal problems, giving up important activities, use in physically hazardous situations, use despite knowing it causes physical or psychological problems, tolerance (needing more to achieve the same effect), and withdrawal symptoms upon cessation.

A Key Point About Recognition: Many people with CUD do not believe they have a problem. The widespread cultural perception that cannabis "isn't addictive" creates a cognitive barrier to recognition that does not exist for most other substances. This is one reason why Motivational Enhancement Therapy -- which helps individuals examine their own relationship with cannabis without pressure -- is often the most effective starting point.

Why Treatment Matters

Left untreated, cannabis use disorder tends to persist and worsen. While some individuals do achieve spontaneous remission, the majority of people with moderate to severe CUD will not simply "grow out of it" without intervention. The consequences of untreated CUD include:

Functional Impairment

CUD impairs performance at work and school, disrupts relationships, reduces motivation, and narrows the range of activities and interests that give life meaning. Over time, cannabis use becomes the central organizing principle of daily life, displacing the activities, relationships, and goals that previously provided fulfillment.

Mental Health Deterioration

Chronic cannabis use worsens anxiety, depression, and psychotic symptoms over time. While many people begin using cannabis to manage these conditions, the paradox of CUD is that continued use worsens the very conditions it was initially used to treat, creating a self-perpetuating cycle.

Cognitive Effects

Chronic heavy cannabis use impairs memory, attention, processing speed, and executive function. While some cognitive recovery occurs with sustained abstinence, research suggests that prolonged heavy use -- particularly with onset during adolescence -- may cause lasting cognitive deficits.

Escalation Risk

Untreated CUD increases the risk of developing other substance use disorders. While cannabis itself may not be a pharmacological "gateway," having an untreated substance use disorder creates behavioral patterns, social environments, and coping deficits that increase vulnerability to problematic use of other substances.

The Big 3: Evidence-Based Psychotherapies for CUD

Three psychotherapeutic approaches have the strongest evidence base for treating cannabis use disorder. These are not competing alternatives -- they are complementary approaches that work best when combined.

1. Cognitive Behavioral Therapy (CBT)

CBT is the most extensively studied psychotherapy for cannabis use disorder. It operates on the principle that cannabis use is maintained by maladaptive thought patterns and behavioral habits that can be identified, challenged, and changed.

How it works: A CBT therapist helps the individual identify specific triggers for cannabis use (situations, emotions, people, places, times of day), recognize the automatic thoughts that precede use ("I can't relax without it," "Just this once won't hurt," "I deserve this"), develop concrete coping strategies for managing triggers without cannabis, build skills for refusing offers and managing social pressure, and practice these skills through role-playing, homework assignments, and real-world application.

Evidence: CBT has demonstrated consistent efficacy for CUD in randomized controlled trials. A standard course is 12-16 sessions over 3-4 months. CBT produces the most durable long-term effects of any CUD treatment, because the skills learned persist after treatment ends. The Cannabis Youth Treatment (CYT) study, one of the largest adolescent CUD treatment trials, found CBT to be effective across diverse populations.

2. Motivational Enhancement Therapy (MET)

MET is a brief, focused therapy designed to build internal motivation for change. It is particularly effective for individuals who are ambivalent about their cannabis use -- those who recognize some problems but are not yet committed to stopping.

How it works: Rather than telling the patient they have a problem and need to change (which tends to provoke resistance), MET uses a collaborative, non-confrontational approach. The therapist guides the individual through structured exploration of their relationship with cannabis, helping them identify their own reasons for concern, recognize the discrepancy between their current behavior and their values or goals, and build their own commitment to change from the inside out. MET does not prescribe what the patient should do -- it helps them discover what they want to do.

Evidence: MET is typically delivered in 2-4 sessions and has demonstrated efficacy as both a standalone brief intervention and as a precursor to CBT. The combination of 2 MET sessions followed by CBT is one of the most well-studied treatment protocols for CUD. MET is particularly effective with adolescents, who often respond poorly to directive approaches but engage well with a therapist who respects their autonomy.

3. Contingency Management (CM)

Contingency management provides tangible, immediate rewards for achieving specific treatment goals -- typically negative urine drug tests. It operates on the behavioral principle that behavior that is reinforced is repeated.

How it works: Patients earn vouchers, prizes, or other tangible rewards for providing cannabis-negative urine samples. The value of rewards typically escalates with consecutive negative tests, creating increasing motivation to maintain abstinence. If a positive test occurs, the reward value resets to baseline, providing a natural consequence for use without punishment or shaming.

Evidence: CM has the strongest immediate effect on cannabis use reduction of any single intervention. It is particularly effective at initiating abstinence during the critical early weeks of treatment. However, the effects of CM alone tend to diminish after the reinforcement period ends, which is why it works best when combined with CBT or MET to build lasting behavioral change. CM also faces practical implementation barriers: it requires regular drug testing and a budget for incentives, which limits its availability in many clinical settings. The VA has implemented CM for stimulant use disorder, demonstrating that it can be scaled within large healthcare systems.

Combination Approaches: Better Together

Research consistently shows that combining treatment modalities produces better outcomes than any single approach alone. The most studied and effective combination for CUD is:

The Gold Standard Protocol: MET + CBT + CM

Sessions 1-2: Motivational Enhancement Therapy -- Build motivation, resolve ambivalence, establish treatment goals.
Sessions 3-14: Cognitive Behavioral Therapy -- Identify triggers, develop coping strategies, build refusal skills, practice real-world application.
Throughout: Contingency Management -- Reinforce abstinence with escalating rewards for negative drug tests.

This protocol was tested in the Marijuana Treatment Project (MTP), one of the largest multisite CUD treatment trials. The combination of all three approaches produced the best outcomes at both end-of-treatment and follow-up, with 37% of participants achieving sustained abstinence at 15-month follow-up -- compared to 17% receiving MET alone and 23% receiving MET + CBT without CM.

The Medication Gap: What Is in the Pipeline

The absence of FDA-approved medications for cannabis use disorder is one of the most significant gaps in the addiction treatment landscape. For comparison: alcohol use disorder has naltrexone, acamprosate, and disulfiram. Opioid use disorder has methadone, buprenorphine, and naltrexone. Nicotine has varenicline, bupropion, and nicotine replacement. Cannabis use disorder has nothing. This is not because CUD is less serious -- it is because cannabis pharmacology is complex, regulatory barriers have impeded research, and the cultural minimization of cannabis addiction has reduced funding priority.

Several promising candidates are currently under investigation:

Medication	Mechanism	Evidence Status
N-Acetylcysteine (NAC)	Glutamate modulation; restores glutamate homeostasis	Promising in adolescent trials; mixed results in adults. Well-tolerated.
Gabapentin	GABA modulation; reduces withdrawal symptoms	Modest benefit for use reduction and withdrawal management in pilot studies.
Nabiximols (Sativex)	THC/CBD combination; partial agonist replacement	Reduced withdrawal severity in controlled trials. Approved in some countries for MS spasticity.
FAAH Inhibitors	Blocks endocannabinoid degradation; stabilizes ECS	Early-stage research. Theoretically promising for reducing withdrawal and craving.
Oxytocin	Modulates stress response and social reward	Preliminary data suggest potential benefit for craving reduction. Very early stage.

While no medication has yet met the bar for FDA approval, medications can play an important indirect role in CUD treatment by addressing co-occurring conditions. SSRIs for depression, stimulants for ADHD, and anxiolytics for anxiety disorders can reduce the self-medication drive that perpetuates cannabis use. This pharmacological approach to comorbidities is a critical component of Dr. Sultan's clinical approach at Integrative Psych.

Sultan's PAWS Project: AI-Powered Digital Therapeutic

One of the fundamental challenges of CUD treatment is the time gap. Most therapy happens during a 50-minute session once a week. But cannabis cravings, triggers, and high-risk situations occur throughout the other 167 hours of the week. What happens when a patient faces a powerful craving at 11 PM on a Saturday and their next therapy appointment is on Wednesday?

PAWS (Personalized AI Wellness System) is an AI-powered digital therapeutic for cannabis use disorder being developed by Dr. Ryan Sultan's research team at Columbia University Irving Medical Center. PAWS is designed to bridge this treatment gap by providing personalized, evidence-based therapeutic support through a mobile application -- available whenever and wherever the patient needs it.

How PAWS Works

Personalized Interventions: PAWS uses artificial intelligence to learn each user's specific triggers, patterns, and responses, delivering increasingly tailored therapeutic content over time.
Real-Time Craving Support: When users experience cravings or face high-risk situations, PAWS provides immediate, evidence-based coping strategies drawn from CBT, MET, and mindfulness frameworks.
Between-Session Continuity: PAWS maintains therapeutic engagement between clinical sessions, reinforcing skills learned in therapy and tracking progress over time.
Data-Driven Clinical Insights: The system provides clinicians with data on patient engagement, craving patterns, and trigger exposure, enabling more targeted and efficient therapy sessions.

PAWS represents the intersection of Dr. Sultan's two areas of expertise: cannabis use disorder treatment and AI in psychiatry. Digital therapeutics have already demonstrated efficacy for substance use disorders -- reSET-O (FDA-cleared for opioid use disorder) showed that adding a digital therapeutic to standard treatment increased abstinence rates. PAWS aims to bring this approach to cannabis use disorder, a condition with no FDA-approved pharmacotherapy and limited treatment access. For more on this project, see PAWS Digital Therapeutic.

Treating Comorbid Conditions: The Essential Component

If there is one message to take from this page, it is this: treating cannabis use disorder without treating co-occurring mental health conditions is setting up the patient to fail. The majority of individuals with CUD have at least one co-occurring psychiatric condition, and in most cases, the cannabis use is driven at least in part by self-medication of that condition.

ADHD and Cannabis Use Disorder

ADHD is one of the most common comorbidities with CUD, and it is one of the most undertreated. Individuals with untreated ADHD often use cannabis to manage restlessness, racing thoughts, and difficulty "shutting off" their brain at night. Appropriate ADHD treatment -- including stimulant medication when indicated -- can significantly reduce the self-medication drive. Research shows that treating ADHD with medication does NOT increase substance use risk; in fact, it reduces it.

Depression and Cannabis Use Disorder

Depression and CUD frequently co-occur, with each condition worsening the other. Cannabis may temporarily relieve depressive symptoms but disrupts serotonin and dopamine systems in ways that deepen depression over time. Effective depression treatment -- SSRIs, therapy, or combination -- can break this cycle. Integrated treatment that addresses both conditions simultaneously produces better outcomes than sequential treatment.

Anxiety and Cannabis Use Disorder

Anxiety disorders -- including generalized anxiety, social anxiety, and PTSD -- are among the most common drivers of cannabis use. The short-term anxiolytic effect of low-dose THC creates a powerful reinforcement loop. However, chronic cannabis use increases baseline anxiety, and high-potency products can trigger panic attacks and exacerbate anxiety disorders. Treating the underlying anxiety with evidence-based approaches (CBT for anxiety, exposure therapy, medication when appropriate) eliminates the need for self-medication.

Adolescent-Specific Treatment Considerations

Treating cannabis use disorder in adolescents requires a different approach than treating adults. Teens have different developmental needs, different motivational structures, and different treatment engagement challenges.

Family Involvement Is Essential

Unlike adult CUD treatment, adolescent treatment should almost always involve the family. Multidimensional Family Therapy (MDFT) and Functional Family Therapy (FFT) are among the most effective treatments for adolescent substance use because they address the family system, improve communication, and strengthen the parent-child relationship. The family environment is a more powerful determinant of adolescent outcomes than any individual therapy.

Motivation Is Different

Teens rarely present for treatment voluntarily. They are usually brought by parents, referred by schools, or mandated by courts. This means that building motivation is the starting point, not the end point, of treatment. MET is particularly valuable with adolescents because it meets them where they are and helps them find their own reasons for change rather than imposing adult priorities.

Developmental Considerations

Adolescent treatment must account for developmental context: the powerful influence of peers, the drive for autonomy, the developing capacity for abstract thinking, and the particular vulnerability of the adolescent brain. Treatment should build life skills alongside substance-specific skills, because teens may not yet have developed the coping repertoire that adults take for granted.

Retention Is the Critical Challenge

Only 36.8% of adolescents completed CUD treatment between 2018 and 2021 (TEDS). This retention crisis is the single biggest barrier to effective adolescent CUD treatment. Factors contributing to dropout include low motivation, parental disengagement, scheduling conflicts, stigma, and the perception that treatment is not relevant. Successful programs prioritize engagement over compliance.

What to Expect in Treatment

Treatment Timeline

Week 1-2: Comprehensive evaluation. Assess CUD severity, identify comorbidities, understand motivation, set goals. Begin withdrawal management if applicable. Withdrawal symptoms (irritability, insomnia, decreased appetite, anxiety) typically peak in the first week and resolve within 2-4 weeks.
Week 2-4: Active early treatment. Begin MET to build motivation, start CBT skill-building. This is the highest-risk period for relapse. Focus on managing cravings, establishing routines, and building early momentum.
Week 4-12: Core treatment phase. Weekly CBT sessions targeting triggers, coping skills, and behavioral change. Treat comorbidities in parallel. Most individuals notice significant improvement in cognition, mood, and sleep during this period.
Month 3-6: Consolidation and maintenance. Reduce session frequency as stability improves. Focus on relapse prevention, building a cannabis-free social network, and maintaining gains.
Beyond 6 months: Ongoing support as needed. Some individuals benefit from monthly check-ins, support groups, or continued digital therapeutic engagement (like PAWS). Recovery is a process, not a destination.

Recovery Outcomes: What the Data Shows

Recovery from cannabis use disorder is achievable. The evidence is clear that treatment works -- though the treatment landscape for CUD produces more modest effect sizes than treatments for some other substance use disorders, reflecting both the complexity of cannabis pharmacology and the lack of FDA-approved medications.

In the Marijuana Treatment Project (MTP), the combination of MET + CBT + CM produced a 37% sustained abstinence rate at 15-month follow-up. While this may seem modest, it represents a clinically significant difference from the natural course of untreated CUD. Even among those who do not achieve full abstinence, treatment typically produces significant reductions in use frequency, improvement in functioning, and better management of comorbid conditions.

Key predictors of good treatment outcomes include: higher motivation at treatment entry, treatment completion (rather than dropout), successful management of comorbid psychiatric conditions, strong social support, and engagement in follow-up care. The single strongest predictor of poor outcome is premature treatment discontinuation.

Relapse Prevention

Relapse is common in CUD recovery and should be understood as a normal part of the process, not a failure. Research on relapse prevention has identified several high-risk situations and effective strategies for managing them.

Common Relapse Triggers

Internal Triggers

Stress and emotional distress
Boredom and under-stimulation
Insomnia (especially in early recovery)
Untreated anxiety or depression
Overconfidence ("I can handle just once")
Nostalgia for the cannabis experience

External Triggers

Social situations where cannabis is present
Old using friends or environments
Celebrations or perceived "safe" occasions
Cannabis advertising and social media
Conflict in relationships
Major life transitions or losses

Effective relapse prevention strategies include: maintaining therapy (even at reduced frequency), developing a strong sober social network, building alternative coping strategies for stress and negative emotions, establishing healthy routines (exercise, sleep hygiene, structured daily activities), ongoing treatment of comorbid conditions, and having a concrete relapse response plan that includes immediate steps to take if use occurs (contact therapist, attend a session, identify what triggered the lapse, recommit to treatment goals without shame).

For more information on cannabis addiction and dependence, see Is Cannabis Addictive?.

Dr. Sultan's Clinical Approach at Integrative Psych

As Director of Integrative Psych NYC and an NIH NIDA-funded researcher at Columbia University, Dr. Sultan brings both clinical expertise and cutting-edge research knowledge to the treatment of cannabis use disorder. His approach is characterized by:

Comprehensive evaluation that goes beyond the cannabis use itself to identify co-occurring conditions, understand the function of cannabis use for the individual, and develop a treatment plan that addresses root causes.
Evidence-based treatment combining CBT, MET, and pharmacotherapy for comorbidities as indicated by the clinical picture.
Research-informed practice that incorporates the latest findings on cannabis pharmacology, neuroscience, and treatment outcomes into clinical decision-making.
Pragmatic approach that meets patients where they are -- whether their goal is full abstinence, reduction, or harm minimization -- and works collaboratively toward improvement.
Integration of technology including digital therapeutic tools to extend treatment beyond the office visit.

Frequently Asked Questions About CUD Treatment

Q: What is the most effective treatment for cannabis use disorder?

A: The most effective approach combines Cognitive Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), and Contingency Management (CM). The MTP trial showed that this combination produced 37% sustained abstinence at 15 months. Treating co-occurring conditions (ADHD, depression, anxiety) is equally critical -- untreated comorbidities are the most common driver of relapse.

Q: Are there medications to treat cannabis use disorder?

A: There are currently no FDA-approved medications specifically for CUD. This is a critical gap. N-acetylcysteine (NAC), gabapentin, nabiximols, and FAAH inhibitors are under investigation. Medications for co-occurring conditions (SSRIs for depression, stimulants for ADHD) can indirectly improve CUD outcomes by treating the conditions driving cannabis use.

Q: How long does treatment for cannabis use disorder take?

A: A standard MET/CBT course is 12-16 sessions over 3-4 months. Some individuals improve within this timeframe; others need longer support. Adolescents may need 3-6 months of active treatment plus follow-up. The strongest predictor of poor outcome is premature discontinuation -- only 36.8% of adolescents complete treatment. Recovery is best understood as an ongoing process.

Q: What is the PAWS digital therapeutic for cannabis use disorder?

A: PAWS (Personalized AI Wellness System) is an AI-powered digital therapeutic being developed by Dr. Sultan's team at Columbia University. It delivers personalized, evidence-based interventions through a mobile app, providing real-time support during cravings and triggers between therapy sessions. PAWS adapts to individual user patterns and bridges the gap between weekly sessions and the 167 other hours of the week.

Q: Can you treat cannabis use disorder if someone also has ADHD or depression?

A: Yes, and treating comorbidities is essential. The majority of people with CUD have at least one co-occurring condition, and untreated ADHD, depression, or anxiety frequently drives cannabis use. An integrated approach that treats both conditions simultaneously produces far better outcomes than addressing them separately. Appropriate ADHD medication, for example, can reduce the self-medication drive.

Q: What should I expect during treatment for cannabis use disorder?

A: Treatment begins with comprehensive evaluation to assess severity and identify co-occurring conditions. Withdrawal symptoms (irritability, insomnia, decreased appetite) typically peak in the first week and resolve within 2-4 weeks. Active treatment focuses on building coping skills through therapy. Most people notice cognitive, mood, and sleep improvements within 2-4 weeks of cessation. Sessions are typically weekly, with progress measured by reduced use, improved functioning, and personal recovery goals.

Related Resources

Cannabis Use Disorder: Signs & Symptoms

Complete DSM-5 criteria, prevalence data, risk factors, and self-assessment.

CUD Overview →

Is Cannabis Addictive?

The evidence on cannabis addiction, dependence, and the spectrum from use to disorder.

Cannabis Addiction →

PAWS Digital Therapeutic

AI-powered treatment for cannabis use disorder from Dr. Sultan's lab at Columbia.

PAWS Project →

Ready to Address Your Cannabis Use?

Dr. Ryan Sultan provides evidence-based evaluation and treatment for cannabis use disorder at Integrative Psych NYC. As an NIH NIDA-funded researcher at Columbia University, he combines clinical expertise with cutting-edge research to deliver personalized treatment plans.

Schedule a Consultation

Telehealth appointments available | Board-Certified Psychiatrist | Columbia University Faculty

© 2026 Ryan S. Sultan, MD | Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Home | Cannabis & Mental Health | Research | Consultation

The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.